Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity

6 Jun 2021

Abstract excerpt

BACKGROUND: Programmed death-ligand 1 (PD-L1) is the most validated predictive biomarker used for the treatment of head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (ICI). Several gene expression-based signatures surrogate of the activation of IFN-gamma pathway and of the presence of tertiary lymphoid structures (TLS) have also been proposed as potential biomarkers. While they may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Head and Neck Cancer Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34111704
DOI: 10.1016/j.oraloncology.2021.105368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneityPMID 34111704Read ↗

Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.Semantic proximity Read ↗

Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinomaSemantic proximity Read ↗

Heterogeneity of PD-L1 expression on tumor cells and tumor-infiltrating immune cells between the primary tumor and matched lymph node metastases in head and neck squamous cell carcinomasSemantic proximity Read ↗

Evaluation of Alcohol, Tobacco, and HPV’s Synergistic regulation of Head and Neck Squamous Cell Carcinoma Treatment Response to PD-L1 Checkpoint Inhibitor TreatmentSemantic proximity Read ↗

Integrated Histopathology–Transcriptomic Biomarker Enhances Survival Prediction in HNSCC Patients Treated with ImmunotherapySemantic proximity Read ↗

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity Read ↗

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.Semantic proximity Read ↗

High-Sensitivity PD-L1 Staining Using Clone 73-10 Antibody and Spatial Transcriptomics for Precise Expression Analysis in Non-Tumorous, Intraepithelial neoplasia, and Squamous Cell Carcinoma of Head and NeckSemantic proximity Read ↗

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapiesSemantic proximity Read ↗

Intratumoral Tertiary Lymphoid Structures Promote Survival and Immunotherapy Response in Head Neck Squamous Cell CarcinomaSemantic proximity Read ↗

CD274/PD-L1gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavitySemantic proximity Read ↗

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.